Funding
Connecta Therapeutics raises $3.5M for Fragile X syndrome Phase IIa trial
September 14, 2026
Biotech
Funding
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
Connecta Therapeutics, Clave Capital, Inveready, CDTI Innvierte, Prous Institute for Biomedical Research
Date
September 14, 2026
Connecta Therapeutics raised $3.5 million in a financing round led by Clave Capital through its Innvierte Science Tech Clave Innohealth fund, with continued support from existing investors Inveready, CDTI Innvierte, and Prous Institute for Biomedical Research. The capital will fund the completion of its ongoing Phase IIa clinical trial of CTH120 in adult males with Fragile X syndrome, with results expected by mid-2027.
The funding directly impacts Connecta Therapeutics, its investors, and the Fragile X syndrome community—a rare neurodevelopmental disorder with no approved disease-modifying treatments. The company is also positioning CTH120 for pediatric expansion through the FRAXCURE project, co-funded by the EIC Accelerator, which will open future market opportunities if Phase IIa data is supportive.
The $3.5M raise is a discrete funding trigger in an allowed geography (Spain), indicating near-term capital needs and BD activity ahead of a planned next financing round. This creates immediate relevance for sales reps targeting biotech clinical trial operations, data management, and business development tools.
Watch for Phase IIa data readout mid-2027 and the subsequent financing round; Connecta’s CSO stated they aim to raise capital against meaningful clinical value inflection points. Also monitor pediatric development milestones under the FRAXCURE project. SDRs should engage now, ahead of Phase IIb planning and vendor selection.
Source:
BioXconomyGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
